Type I/II Interferon Balance in the Regulation of Brain Physiology and Pathology

Trends in Immunology

Volumn 37, Issue 3, 2016, Pages 181-192

  Deczkowska, Aleksandra ^a   Baruch, Kuti ^a   Schwartz, Michal ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Aging; Choroid plexus; CNS immune surveillance; Interferons; Neurodegeneration

Indexed keywords

GAMMA INTERFERON; INTERFERON;

AGING; AUTOIMMUNE DISEASE; BRAIN AGING; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; LEUKOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; ANIMAL; AUTOIMMUNITY; BRAIN; HOMEOSTASIS; IMMUNOLOGY; PHYSIOLOGY;

AGING; ANIMALS; AUTOIMMUNITY; BRAIN; HOMEOSTASIS; HUMANS; IMMUNOLOGIC SURVEILLANCE; INTERFERON TYPE I; INTERFERON-GAMMA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84959315169     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.01.006     Document Type: Review

References (102)

1. Ziv Y., et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 2006, 9:268-275.
2. Wolf S.A., et al. CD4-positive T lymphocytes provide a neuroimmunological link in the control of adult hippocampal neurogenesis. J. Immunol. 2009, 182:3979-3984.
3. Kipnis J., et al. T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:8180-8185.
4. Lewitus G.M., et al. Reducing post-traumatic anxiety by immunization. Brain Behav. Immun. 2008, 22:1108-1114.
5. Schwartz M., Baruch K. The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J. 2014, 33:7-22.
6. Kipnis J., et al. Pro-cognitive properties of T cells. Nat. Rev. Immunol. 2012, 12:663-669.
7. Shechter R., et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med. 2009, 6:e1000113.
8. London A., et al. Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages. J. Exp. Med. 2011, 208:23-39.
9. Gliem M., et al. Protective features of peripheral monocytes/macrophages in stroke. Biochim. Biophys. Acta 2015, Published online November 12, 2015. 10.1016/j.bbadis.2015.11.004.
10. + monocytes: the hidden side of Alzheimer's disease. J. Mol. Cell Biol. 2013, 5:284-293.
11. Town T., et al. Blocking TGF-b-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 2008, 14:681-687.
12. Hawkes C.A., McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:1261-1266.
13. El Khoury J., et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007, 13:432-438.
14. + monocytes in a mouse model of Alzheimer's disease. Brain 2015, 138:2399-2422.
15. + regulatory T cells mitigates Alzheimer's disease pathology. Nat. Commun. 2015, 6:7967.
16. Rezai-Zadeh K., et al. CNS infiltration of peripheral immune cells: D-day for neurodegenerative disease?. J. Neuroimmune Pharmacol. 2009, 4:462-475.
17. Derecki N.C., et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012, 484:105-109.
18. Raposo C., et al. CNS repair requires both effector and regulatory T cells with distinct temporal and spatial profiles. J. Neurosci. 2014, 34:10141-10155.
19. Moalem G., et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 1999, 5:49-55.
20. Derecki N.C., et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J. Exp. Med. 2010, 207:1067-1080.
21. Gadani S.P., et al. IL-4 in the brain: a cytokine to remember. J. Immunol. 2012, 189:4213-4219.
22. Ottum P.A., et al. Opposing roles of interferon-gamma on cells of the central nervous system in autoimmune neuroinflammation. Front. Immunol. 2015, 6:539.
23. Appel S.H., et al. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?. Trends Immunol. 2010, 31:7-17.
24. Fisher Y., et al. Th1 polarization of T cells injected into the cerebrospinal fluid induces brain immunosurveillance. J. Immunol. 2014, 192:92-102.
25. Ransohoff R.M., Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. 2012, 12:623-635.
26. Engelhardt B., Ransohoff R.M. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005, 26:485-495.
27. Johanson C.E., et al. The blood-cerebrospinal fluid barrier: structure and functional significance. Methods Mol. Biol. 2005, 686:101-131.
28. Mortazavi M.M., et al. The choroid plexus: a comprehensive review of its history, anatomy, function, histology, embryology, and surgical considerations. Childs Nerv. Syst. 2014, 30:205-214.
29. Baruch K., et al. CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:2264-2269.
30. Anandasabapathy N., et al. Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain. J. Exp. Med. 2011, 208:1695-1705.
31. Henry R.A., et al. AAV-mediated delivery of BDNF augments neurogenesis in the normal and quinolinic acid-lesioned adult rat brain. Eur. J. Neurosci. 2007, 25:3513-3525.
32. Llorens-Martin M., et al. Mechanisms mediating brain plasticity: IGF1 and adult hippocampal neurogenesis. Neuroscientist 2009, 15:134-148.
33. Falcao A.M., et al. The path from the choroid plexus to the subventricular zone: go with the flow!. Front. Cell. Neurosci. 2012, 6:34.
34. Baruch K., et al. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 2014, 346:89-93.
35. + T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8389-8394.
36. Shechter R., et al. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat. Rev. Immunol. 2013, 13:206-218.
37. Kunis G., et al. IFN-gamma-dependent activation of the brain's choroid plexus for CNS immune surveillance and repair. Brain 2013, 136:3427-3440.
38. Phillips L.K., et al. Natural killer cell-activating receptor NKG2D mediates innate immune targeting of allogeneic neural progenitor cell grafts. Stem Cells 2013, 31:1829-1839.
39. Stammers A., et al. Expression of inflammatory cytokines following acute spinal cord injury in a rodent model. J. Neurosci. Res. 2012, 90:782-790.
40. Baruch K., et al. Cerebral nitric oxide represses choroid plexus NFκB-dependent gateway activity for leukocyte trafficking. EMBO J. 2015, 34:1816-1829.
41. + monocytes in a mouse model of Alzheimer's disease. Brain 2015, 138:2399-2422.
42. Mesquita S.D., et al. The choroid plexus transcriptome reveals changes in type I and II interferon responses in a mouse model of Alzheimer's disease. Brain Behav. Immun. 2015, 49:280-292.
43. Kunis G., et al. Immunization with a myelin-derived antigen activates the brain's choroid plexus for recruitment of immunoregulatory cells to the CNS and attenuates disease progression in a mouse model of ALS. J. Neurosci. 2015, 35:6381-6393.
44. Endo F., et al. Astrocyte-derived TGF-β1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 2015, 11:592-604.
45. Dendrou C.A., et al. Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 2015, 15:545-558.
46. Larochelle C., et al. How do immune cells overcome the blood-brain barrier in multiple sclerosis?. FEBS Lett. 2011, 585:3770-3780.
47. Pestka S., et al. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202:8-32.
48. Gonzalez-Navajas J.M., et al. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 2012, 12:125-135.
49. Schreiber G., Piehler J. The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol. 2015, 36:139-149.
50. Hodgkin P.D., et al. The clonal selection theory: 50 years since the revolution. Nat. Immunol. 2007, 8:1019-1026.
51. Merbl Y., et al. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J. Clin. Invest. 2007, 117:712-718.
52. Madi A., et al. T-cell receptor repertoires share a restricted set of public and abundant CDR3 sequences that are associated with self-related immunity. Genome Res. 2014, 24:1603-1612.
53. Okazaki T., et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 2013, 14:1212-1218.
54. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22:531-562.
55. Kong Y.C., Flynn J.C. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front. Immunol. 2014, 5:206.
56. Becher B. Central nervous system immune surveillance: on natalizumab, dendritic cells, and dangerous immune privilege. Arch. Neurol. 2008, 65:1566-1567.
57. Stromnes I.M., et al. Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells. Nat. Med. 2008, 14:337-342.
58. Ransohoff R.M., et al. Multiple sclerosis - a quiet revolution. Nat. Rev. Neurol. 2015, 11:134-142.
59. Yednock T.A., et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66.
60. Kocur M., et al. IFNb secreted by microglia mediates clearance of myelin debris in CNS autoimmunity. Acta Neuropathol. Commun. 2015, 3:20.
61. Teige I., et al. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 2003, 170:4776-4784.
62. Prinz M., et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008, 28:675-686.
63. Limmroth V., et al. The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther. Adv. Neurol. Dis. 2011, 4:281-296.
64. Kasper L.H., Reder A.T. Immunomodulatory activity of interferon-beta. Ann. Clin. Transl. Neurol. 2014, 1:622-631.
65. Lees J.R., et al. Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J. Exp. Med. 2008, 205:2633-2642.
66. Axtell R.C., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 2010, 16:406-412.
67. Axtell R.C., Raman C. Janus-like effects of type I interferon in autoimmune diseases. Immunol. Rev. 2012, 248:23-35.
68. Axtell R.C., et al. Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin. Rev. Allergy Immunol. 2013, 44:114-120.
69. Kim S.H., et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?. Mult. Scler. 2012, 18:1480-1483.
70. Higgs B.W., et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann. Rheum. Dis. 2014, 73:256-262.
71. Nacionales D.C., et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 2007, 56:3770-3783.
72. La Mantia L., et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst. Rev. 2012, 1:CD005181.
73. Lassmann H., et al. Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 2012, 8:647-656.
74. Waisman A., et al. Innate and adaptive immune responses in the CNS. Lancet Neurol. 2015, 14:945-955.
75. Russo M.V., McGavern D.B. Immune 2urveillance of the CNS following infection and injury. Trends Immunol. 2015, 36:637-650.
76. Crow M.K. Type I interferon in the pathogenesis of lupus. J. Immunol. 2014, 192:5459-5468.
77. Crow Y.J., Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat. Rev. Immunol. 2015, 15:429-440.
78. Rothhammer V., et al. Th17 lymphocytes traffic to the central nervous system independently of alpha4 integrin expression during EAE. J. Exp. Med. 2011, 208:2465-2476.
79. Reboldi A., et al. CC chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 2009, 10:514-523.
80. Kurschus F.C., et al. Genetic proof for the transient nature of the Th17 phenotype. Eur. J. Immunol. 2010, 40:3336-3346.
81. Duhen R., et al. Cutting edge: the pathogenicity of IFN-γ-producing Th17 cells is independent of T-bet. J. Immunol. 2013, 190:4478-4482.
82. Chong W.P., et al. NK-DC crosstalk controls the autopathogenic Th17 response through an innate IFN-γ-IL-27 axis. J. Exp. Med. 2015, 212:1739-1752.
83. Croxford A.L., et al. Mouse models for multiple sclerosis: historical facts and future implications. Biochim. Biophys. Acta Mol. Basis Dis. 2011, 1812:177-183.
84. Ransohoff R.M. Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat. Neurosci. 2012, 15:1074-1077.
85. Gabuzda D., Yankner B.A. Physiology: inflammation links ageing to the brain. Nature 2013, 497:197-198.
86. Krstic D., et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J. Neuroinflammation 2012, 9:151.
87. Wilson E.B., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
88. Teijaro J.R., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
89. Sandler N.G., et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 2014, 511:601-605.
90. Teles R.M., et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 2013, 339:1448-1453.
91. Villeda S.A., et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011, 477:90-94.
92. Prinz M., Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat. Rev. Neurosci. 2014, 15:300-312.
93. Cohen M., et al. Chronic exposure to TGFb1 regulates myeloid cell inflammatory response in an IRF7-dependent manner. EMBO J. 2014, 33:2906-2921.
94. Goldmann T., et al. USP18 lack in microglia causes destructive interferonopathy of the mouse brain. EMBO J. 2015, 34:1612-1629.
95. Taylor J.M., et al. Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease. Neurobiol. Aging 2014, 35:1012-1023.
96. Ejlerskov P., et al. Lack of neuronal IFN-β-IFNAR causes Lewy body- and Parkinson's disease-like dementia. Cell 2015, 163:324-339.
97. Gough D.J., et al. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012, 36:166-174.
98. Lin C-W., et al. Spinal cord injury is related to an increased risk of multiple sclerosis: a population-based, propensity score-matched, longitudinal follow-up study. J. Neurotrauma 2015, 32:655-659.
99. Ron-Harel N., Schwartz M. Immune senescence and brain aging: can rejuvenation of immunity reverse memory loss?. Trends Neurosci. 2009, 32:367-375.
100. Kleine T.O. Cellular immune surveillance of central nervous system bypasses blood-brain barrier and blood-cerebrospinal-fluid barrier: Revealed with the New Marburg cerebrospinal-fluid model in healthy humans. Cytometry A 2015, 87:227-243.
101. Schwerk C., et al. The choroid plexus - a multi-role player during infectious diseases of the CNS. Front. Cell. Neurosci. 2015, 9:80.
102. Ransohoff R.M., et al. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 2003, 3:569-581.